期刊文献+

AQP-1和AQP-5在卵巢上皮性肿瘤的表达及临床意义 被引量:9

The Expression of Aquaporin-1 and Aquaporin-5 in Epithelial Ovarian Tumors and Its Clinic Signifiance.
在线阅读 下载PDF
导出
摘要 目的探讨AQP1及AQP5在卵巢上皮性肿瘤的表达及临床意义。方法采用免疫组化法检测105例卵巢上皮性肿瘤和10例正常卵巢组织AQP1和AQP5蛋白的表达。结果AQP1主要表达于毛细血管及小血管内皮细胞,而AQP5表达于卵巢肿瘤细胞。随着卵巢上皮性肿瘤由良性向恶性发展,AQP1和AQP5的表达逐渐增加(P<0.05)。Ⅲ、Ⅳ期卵巢癌AQP1的表达明显高于Ⅰ、Ⅱ期(P<0.05),伴淋巴转移者AQP1明显高于无淋巴转移者(P<0.05);腹水大于1000 mL者AQP1和AQP5的表达明显高于小于1000 mL者(P<0.01);低分化卵巢癌AQP5的表达明显高于高、中分化者(P<0.05);AQP1及AQP5的表达与腹水量呈正相关(r分别为0.40,0.31;P<0.05)。结论AQP1和AQP5高表达与卵巢癌的发生、发展及预后有关,可能是卵巢癌腹水产生的主要原因。 Objective To investigate expression of aquaporin-1 (AQPI) and aquaporin-5 (AQPS) in epithelial ovarian tumors and its clinic significance. Methods The expression of AQPl and AQP5 were measured by immunohistochemical technique in 10 cases normal tissue and 125 cases epithelial ovarian tumors. Results AQP1 is located in microvascular and small vessel endothelial cells, and AQP5 in tumor cells. Expression of AQP1 and AQP5 increased in ovarian cancer was significant higher than that of borderline tumors (P〈0.05). Expression of AQP1 in borderline tumors is significant higher than that of normal tissue (P〈0.05) and expression of AQP5 in borderline tumors higher than that of benign tumors (P〈0.05). Expression of AQP1 in FIGO stage Ⅲ-Ⅳ more than that of stage Ⅰ-Ⅱ (P〈0.05) and cases with lymph node metastasis higher than without lymph node metastasis (P〈0.05). Expression of AQP1 and AQP5 in ascites amount more than 1000 mL higher than that of ascites amount less than 1000 mL (P〈0.01);Expression of AQP1 and AQP5 were positively correlated with ascites amount (P〈0.05). Conclusions: There is a intimate relationship between high expression of AQPI and AQP5 and development of epithelial ovarian cancer as well as prognosis,which may be a important cause resulting in ascites formation.
出处 《科技通报》 2006年第6期781-784,791,共5页 Bulletin of Science and Technology
关键词 卵巢肿瘤 AQP1 AQP5 腹水 免疫组织化学 epithelial ovarian tumor AQP1 AQP5 ascites immunohistochemistry
作者简介 杨建华(1967-),女,河南洛阳人,博士,副主任医师,现在浙江大学附属二院工作。 通讯作者:石一复,教授,博士导师
  • 相关文献

参考文献1

二级参考文献21

  • 1Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10: 575-600.
  • 2Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995; 64: 375-401.
  • 3Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and Nhydroxysulfonamides inhibit both these zinc enzymes.J Med Chem 2000; 43: 3677-87.
  • 4Webb SD, Sherratt JA, Fish RG. Mathematical modelling of tumour acidity: regulation of intracellular pH. J Theor Biol 1999; 196: 237-50.
  • 5Gerweck LE. Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 1998; 8: 176-82.
  • 6Helmlinger G, Yuan E Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-82.
  • 7Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241-63.
  • 8Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE,et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95: 12596-601.
  • 9Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A,Pastorekova S, et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 2000; 97: 2220-4.
  • 10Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549-56.

共引文献24

同被引文献56

引证文献9

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部